RNAi-based therapies for Huntingtons disease: Delivery challenges and opportunities

Therapeutic Delivery

Volumn 3, Issue 9, 2012, Pages 1061-1076

  Mantha, Neelima ^a   Das, Sudip K ^a   Das, Nandita G ^a  

^a BUTLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTIDEPRESSANT AGENT; ANTIOXIDANT; APOPTOSIS INHIBITOR; BACULOVIRUS VECTOR; BREAST CANCER RESISTANCE PROTEIN; CELL PENETRATING PEPTIDE; CHITOSAN; CHOLESTEROL; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOUBLE STRANDED RNA; GLUTAMATE RECEPTOR ANTAGONIST; HUNTINGTIN; LENTIVIRUS VECTOR; LIPOSOME; MACROGOL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PARVOVIRUS VECTOR; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYGLUTAMINE; RETROVIRUS VECTOR; RNA INDUCED SILENCING COMPLEX; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TETRABENAZINE; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

3' UNTRANSLATED REGION; CHEMICAL MODIFICATION; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE COURSE; DISEASE MODEL; DOPAMINE UPTAKE; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; GENE; GENE MUTATION; GENE SILENCING; HALLUCINATION; HTT GENE; HUMAN; HUNTINGTON CHOREA; INHIBITION KINETICS; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENESIS; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SPEECH THERAPY; TRINUCLEOTIDE REPEAT; VIRAL GENE DELIVERY SYSTEM;

EID: 84865766602     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.80     Document Type: Review

References (103)

1. Hardman JG, Limberd LL. The Pharmacological Basis of Therapeutics (10th Edition). Hardman JG, Limberd LL (Eds). McGrew Hill, New York, NY, USA (2001).
2. MacDonald ME, Ambrose CM, Duyao MP et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 6, 971-983 (1993). (Pubitemid 23110238)
3. Kumar P, Kalonia H, Kumar A. Huntington's disease: pathogenesis to animal models. Pharmacol. Rep. 62(1), 1-14 (2010).
4. Ersoy N. Molecular genetics of Huntington's Disease: when size does matter. J. Cell Mol. Biol. 6(1), 1-8 (2007). (Pubitemid 351802493)
5. Fischbeck KH. Polyglutamine expansion neurodegenerative disease. Brain Res. Bull. 56(3-4), 161-163 (2001). (Pubitemid 33062337)
6. Cummings CJ, Zoghbi HY. Fourteen and counting: unraveling trinucleotide repeat diseases. Human Mol. Genet. 9(6), 909-916 (2000). (Pubitemid 30216102)
7. Krobitsch S, Kazantsev AG. Huntington's disease: from molecular basis to therapeutic advances. Int. J. Biochem. Cell Biol. 43(1), 20-24 (2011). Overview of Huntington's disease.
8. Li SH, Li XJ. Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet. 20(3), 146-154 (2004).
9. Truant R, Atwal RS, Burtnik A. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntington's disease. Prog. Neurobiol. 83(4), 211-227 (2007). (Pubitemid 47595404)
10. Cha JH. Transcriptional dysregulation in Huntington's disease. Trends Neurosci. 23(9), 387-392 (2000).
11. Luthi-Carter R, Hanson SA, Strand AD et al. Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. Hum. Mol. Genet. 11(17), 1911-1926 (2002). Demonstrated functional disruption of genes upon mutant HTT expression.
12. Sugars KL, Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet. 19(5), 233-238 (2003). (Pubitemid 36511427)
13. Wyttenbach A, Swartz J, Kita H et al. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. Hum. Mol. Genet. 10(17), 1829-1845 (2001). (Pubitemid 32899099)
14. Dunah AW, Jeong H, Griffin A et al. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296(5576), 2238-2243 (2002). (Pubitemid 34680312)
15. Wanker EE, Rovira C, Scherzinger E et al. HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system. Hum. Mol. Genet. 6(3), 487-495 (1997). (Pubitemid 27116471)
16. Worseck JM, Grossmann A, Weimann M, Hegele A, Stelzl U. A stringent yeast two-hybrid matrix screening approach for protein-protein interaction discovery. Methods Mol. Biol. 812, 63-87 (2012).
17. Ratovitski T, Chighladze E, Arbez N et al. Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis. Cell Cycle. 11(10), 2006-2021 (2012).
18. Reddy PH, Williams M, Tagle DA. Recent advances in understanding the pathogenesis of Huntington's disease. Trends NeuroSci. 22(6), 248-255 (1999). (Pubitemid 29259990)
19. Tang TS, Tu H, Chan EY et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Neuron. 39(2), 293-297 (2003).
20. Bhattacharyya NP, Banerjee M, Majumder P. Huntington's disease: roles of huntingtin-interacting protein 1 (HIP-1) and its molecular partner HIPPI in the regulation of apoptosis and transcription. FEBS J. 275(17), 4271-4279 (2008).
21. Li S, Li XJ. Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener. 1(16), 19 (2006).
22. Hackam AS, Yassa AS, Singaraja R et al. Huntingtin interacting protein 1 induces apoptosis via a novel caspase-dependent death effector domain. J. Biol. Chem. 275(52), 41299-41308 (2000). (Pubitemid 32054964)
23. Hickey MA, Chesselet MF. Apoptosis in Huntington's disease. Prog. Neuropsychopharmacol. Biol. Psychiary. 27(2), 255-265 (2003). (Pubitemid 36351493)
24. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr. Opin. Neurol. 21(4), 497-503 (2008).
25. Tyagi SN, Tyagi LK, Shekhar R, Singh M, Kori ML. Symptomatic treatment and management of Huntington's disease: an overview. Global J. Pharmacol. 4(1), 6-12 (2010).
26. Sari Y. Potential drugs and methods for preventing or delaying the progression of Huntington's disease. Recent Pat. CNS Drug Discov. 6(2), 80-90 (2011).
27. Handley OJ, Naji JJ, Dunnett SB, Rosser AE. Pharmaceutical, cellular and genetic therapies for Huntington's disease. Clin. Sci. (Lond.). 110(1), 73-88 (2006). (Pubitemid 43059046)
28. Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA based therapeutics. Nat. Rev. Drug Discov. 6, 443-453 (2007). (Pubitemid 47064567)
29. Milhavet O, Gary DS, Mattson MP. RNA interference in biology and medicine. Pharmacol. Rev. 55(4), 629-648 (2003). (Pubitemid 37500523)
30. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 431(7006), 371-378 (2004). (Pubitemid 39265678)
31. Liu J, Carmell MA, Rivas FV et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305(5689), 1437-1441 (2004). (Pubitemid 39167657)
32. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411(6836), 494-497 (2001).
33. Agrawal N, Dasaradhi PV, Mohmmed A, Malhotra P, Bhatnagar RK, Mukherjee SK. RNA interference: biology, mechanism, and applications. Microbiol. Mol. Biol. Rev. 67(4), 657-685 (2003). (Pubitemid 37549773)
34. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8(3), 173-184 (2007).
35. Cullen BR. Transcription and processing of human microRNA precursors. Molecular Cell 16(6), 861-865 (2004). (Pubitemid 40018397)
36. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. 17(24), 3011-3016 (2003). (Pubitemid 38040764)
37. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv. Drug Deliv. Rev. 61(9), 746-759 (2009). Overview of the pros and cons of using siRNA versus shRNA.
38. Rao DD, Senzer N, Cleary MA, Nemunaitis J. Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene. Ther. 16(11), 807-809 (2009).
39. Hornung V, Guenthner-Biller M, Bourquin C et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11(3), 263-270 (2005). (Pubitemid 40460553)
40. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23(4), 457-462 (2005). (Pubitemid 41724921)
41. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J. Clin. Invest. 117(12), 3633-3641 (2007). (Pubitemid 350224069)
42. John M, Constien R, Akinc A et al. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449(7163), 745-747 (2007). (Pubitemid 47552094)
43. Vaishnaw AK, Gollob J, Gamba-Vitalo C et al. A status report on RNAi therapeutics. Silence 1(1), 14 (2010).
44. Aagaard L, Rossi JJ. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Del. Rev. 59(2-3), 75-86 (2007). (Pubitemid 46770900)
45. Boudreau RL, Davidson BL. RNAi therapeutics for CNS disorders. Brain Res. 1338, 112-121 (2010).
46. Harper SQ, Staber PD, He X et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102(16), 5820-5825 (2005). (Pubitemid 40559643)
47. Rodriguez-Lebron E, Denovan-Wright EM, Nash K, Lewin AS, Mandel RJ. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 12(4), 618-633 (2005). (Pubitemid 41350143)
48. Wang YL, Liu W, Wada E, Murata M, Wada K, Kanazawa I. Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. Neurosci. Res. 53(3), 241-249 (2005). (Pubitemid 41463777)
49. Machida Y, Okada T, Kurosawa M, Oyama F, Ozawa K, Nukina N. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem. Biophys. Res. Commun. 343(1), 190-197 (2006).
50. Di Figlia M, Sena-Esteves M, Chase K et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl Acad. Sci. USA 104(43), 17204-17209 (2007). Reported successful delivery of siRNA in an animal model using cholesterol as a vehicle. (Pubitemid 350211015)
51. Huang B, Schiefer J, Sass C, Landwehrmeyer GB, Kosinski CM, Kochanek S. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum. Gene Ther. 18(4), 303-311 (2007). (Pubitemid 46709342)
52. Franich NR, Fitzsimons HL, Fong DM, Klugmann M, During MJ, Young D. AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease. Mol Ther. 16(5), 947-956 (2008). (Pubitemid 351587106)
53. Liu W, Goto J, Wang YL, Murata M, Wada K, Kanazawa I. Specific Inhibition of Huntington's disease gene expression by siRNA's in cultured cells. Proc. Japan Acad. B 79B (10), 293-298 (2003).
54. Huang B, Kochanek S. Adenovirus-mediated silencing of huntingtin expression by shRNA. Hum. Gen. Ther. 16(5), 618-626 (2005). (Pubitemid 40740929)
55. Fiszer A, Olejniczak M, Switonski PM et al. An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases. BMC Mol. Biol. 13 (6) (2012).
56. Gagnon KT, Pendergraff HM, Deleavey GF et al. Allele-selective inhibition of mutant huntingtin expression with antisense oligonucleotides targeting the expanded CAG repeat. Biochemistry 49(47), 10166-10178 (2010).
57. Carroll JB, Warby SC, Southwell AL et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. sms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol. Ther. 19(12), 2178-2185 (2011).
58. Corey DR. Chemical modification: the key to clinical application of RNA interference? J. Clin. Invest. 117(12), 3615-3622 (2007). Principles for chemical modification of siRNA. (Pubitemid 350224067)
59. McBride JL, Pitzer MR, Boudreau RL et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol. Ther. 19(12), 2152-2162 (2011).
60. Grondin R, Kaytor MD, Ai Y et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135(Pt 4), 1197-1209 (2012).
61. Sledz CA, Williams BR. RNA interference in biology and disease. Gene Ther. 106(3), 787-784 (2005).
62. Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther. 12(1), 5-11 (2005). (Pubitemid 40090039)
63. Schlee M, Hornung V, Hartmann G. siRNA and isRNA: two edges of one sword. Mol. Ther. 14(4), 463-470 (2006). (Pubitemid 44296098)
64. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 457(7228), 426-433 (2009).
65. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 455(7209), 58-63 (2008).
66. Birmingham A, Anderson EM, Reynolds A et al. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3(3), 199-204 (2006).
67. Du Q, Thonberg H, Wang J, Wahlestedt C, Liang Z. A systematic analysis of the silencing effects of an active siRNA at all single-nucleotide mismatched target sites. Nucleic Acids Res. 33(5), 1671-1677 (2007). (Pubitemid 41418395)
68. Boudreau RL, Spengler RM, Davidson BL. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol. Ther. 19(12), 2169-2177 (2011). Principles for designing siRNA for minimal off-target effects - includes microarray analyses.
69. Jackson AL, Bartz SR, Schelter J et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21(6), 635-637 (2003). (Pubitemid 36638089)
70. Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 6(3), 686-695 (2009).
71. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
72. Harborth J, Elbashir SM, Vandenburgh K et al. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13(2), 83-105 (2003).
73. Sliva K, Schnierle BS. Selective gene silencing by viral delivery of short hairpin RNA. Virol. J. 7, 248-259 (2010).
74. de Jonge J, Holtrop M W J, Huckriede A. Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther. 13(5), 400-411 (2006).
75. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346-358 (2003). (Pubitemid 36538359)
76. Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgene expression. Br. J. Pharmacol. 157(2), 153-165 (2009).
77. Yin HY, Zhou X, Wu HF, Li B, Zhang YF. Baculovirus vector-mediated transfer of NIS gene into colon tumor cells for radionuclide therapy. World J. Gastroenterol. 16(42), 5367-5374 (2010).
78. Zhang S, Zhao B, Jiang H, Wang B, Ma B. Cationic lipids and polymers mediated vectors for delivery of siRNA. J. Control. Release 123(1), 1-10 (2007). (Pubitemid 47444388)
79. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J. Clin. Invest. 117(12), 3623-3632 (2007). (Pubitemid 350224068)
80. Maclachlan I. Liposomal formulations for nucleic acid delivery. In: Antisense Drug Technology: Principles, Strategies, and Applications. CRC Press, Boca Raton, FL, USA, 237-262 (2008).
81. Gao Y, Liu XL, Li XR. Research progress on siRNA delivery with non-viral carriers. Int. J. Nanomed. 6, 1017-1025 (2011).
82. Kapoor M, Burgess DJ. Efficient and safe delivery of siRNA using anionic lipids: formulation optimization studies. Int. J. Pharm. 432(1-2), 80-90 (2012).
83. Kim SS, Garg H, Joshi A, Manjunath N. Strategies for targeted nonviral delivery of siRNAs in vivo. Trends Mol. Med. 15(11), 491-500 (2009).
84. Zhang C, Tang N, Liu X, Liang W, Xu W, Torchilin VP. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Cont. Rel. 112(2), 229-239 (2006).
85. Schiffelers RM, Ansari A, Xu J et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acid Res. 32(19), e149 (2004).
86. Yuan X, Naguib S, Wu Z. Recent advances of siRNA delivery by nanoparticles. Expert Opin. Drug Deliv. 8(4), 521-536 (2011).
87. Milletti F. Cell-penetrating peptides: classes, origin, and current landscape. Drug Disc. Today. 17(15-16), 850-860 (2012).
88. Madani F, Lindberg S, Langel U, Futaki S, Gräslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J. Biophys. doi:10.1155/2011/ 414729 (2011) (Epub ahead of print).
89. Lundin P, Johansson H, Guterstam P et al. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconj. Chem. 19(12), 2535-2542 (2008).
90. Lehto T, Kurrikoff K, Langel U. Cell-penetrating peptides for the delivery of nucleic acids. Expert Opin. Drug Deliv. 9(7), 823-836 (2012).
91. Mo RH, Zaro JL, Shen WC. Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol. Pharm. 9(2), 299-309 (2012).
92. Abbott NJ. Physiology of the blood-brain barrier and its consequences for drug transport to the brain. Int. Congress Series 1277, 3-18 (2005). (Pubitemid 43693341)
93. Ghosh C, Puvenna V, Gonzalez-Martinez J, Janigro D, Marchi N. Blood-brain barrier P450 enzymes and multidrug transporters in drug resistance: a synergistic role in neurological diseases. Curr. Drug Metab. 12(8), 742-749 (2011).
94. Su Y, Sinko PJ. Drug delivery across the blood-brain barrier: why is it difficult? How to measure and improve it? Expert Opin. Drug Deliv. 3(3), 419-435 (2006). (Pubitemid 43772716)
95. Huang B, Schiefer J, Sass C, Landwehrmeyer GB, Kosinski CM, Kochanek S. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum. Gene Ther. Apr. 18(4), 303-311 (2007). (Pubitemid 46709342)
96. Di Figlia M, Sena-Esteves M, Chase K et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl Acad. Sci. USA 104(43), 17204-17209 (2007). (Pubitemid 350211015)
97. Pulford B, Reim N, Bell A et al. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrPC on neuronal cells and PrPRES ininfected cell cultures. PLoS ONE 5(6), e11085 (2010).
98. Tao Y, Han J, Huanyu D. Brain-targeting gene delivery using a rabies virus glycoprotein peptide modulated hollow liposome: bio-behavioral study. J. Mat. Chem. 22, 11808-11815 (2012).
99. van den Boorn JG, Schlee M, Coch C, Hartmann G. SiRNA delivery with exosome nanoparticles. Nat. Biotech. 29(4), 325-326 (2011).
100. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotech. 29(4), 341-345 (2011).
101. Mathupala SP. Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin. Ther. Pat. 19(2), 137-140 (2009).
102. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 99(4), 1654-1673 (2010).
103. Harper SQ. Progress and challenges in RNA interference therapy for Huntington disease. Neurol. Rev. 66(8), 933-938 (2009).